c-FLIP knockdown induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells

Biochemical Pharmacology

Volumn 76, Issue 12, 2008, Pages 1694-1704

  Day, Travis W ^a   Huang, Su ^a   Safa, Ahmad R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Breast cancer; c FLIP; Small interfering RNA (siRNA); TRAIL receptor 5

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CASPASE 8; CASPASE 9; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; LIGAND; PROTEIN DR5; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

APOPTOSIS; BREAST NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; GENE SILENCING; HUMANS; LIGANDS; PROTEIN ISOFORMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING;

EID: 56549112480     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.09.007     Document Type: Article

References (61)

1. Cereghetti G.M., and Scorrano L. The many shapes of mitochondrial death. Oncogene 25 (2006) 4717-4724
2. Debatin K.M., and Krammer P.H. Death receptors in chemotherapy and cancer. Oncogene 23 (2004) 2950-2966
3. Green D., and Kroemer G. The central executioners of apoptosis: caspases or mitochondria?. Trends Cell Biol 8 (1998) 267-271
4. Ashkenazi A., and Dixit V.M. Death receptors: signaling and modulation. Science 281 (1998) 1305-1308
5. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 (2000) 599-609
6. Li H., Zhu H., Xu C.J., and Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94 (1998) 491-501
7. Gogvadze V., and Orrenius S. Mitochondrial regulation of apoptotic cell death. Chem Biol Interact 163 (2006) 4-14
8. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1996) 147-157
9. Jiang X., and Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 73 (2004) 87-106
10. Strasser A., O'Connor L., and Dixit V.M. Apoptosis signaling. Annu Rev Biochem 69 (2000) 217-245
11. Krueger A., Baumann S., Krammer P.H., and Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21 (2001) 8247-8254
12. Gao S., Wang H., Lee P., Melamed J., Li C.X., Zhang F., et al. Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol 36 (2006) 463-483
13. Morales J.C., Ruiz-Magana M.J., and Ruiz-Ruiz C. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition. Mol Immunol 44 (2007) 2587-2597
14. Valnet-Rabier M.B., Challier B., Thiebault S., Angonin R., Margueritte G., Mougin C., et al. c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol 128 (2005) 767-773
15. Steele L.P., Georgopoulos N.T., Southgate J., Selby P.J., and Trejdosiewicz L.K. Differential susceptibility to TRAIL of normal versus malignant human urothelial cells. Cell Death Differ 13 (2006) 1564-1576
16. Mezzanzanica D., Balladore E., Turatti F., Luison E., Alberti P., Bagnoli M., et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res 10 (2004) 5202-5214
17. Ullenhag G.J., Mukherjee A., Watson N.F., Al-Attar A.H., Scholefield J.H., and Durrant L.G. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 13 (2007) 5070-5075
18. Song J.H., Song D.K., Herlyn M., Petruk K.C., and Hao C. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin Cancer Res 9 (2003) 4255-4266
19. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J 326 (1997) 1-16
20. Golks A., Brenner D., Fritsch C., Krammer P.H., and Lavrik I.N. c-FLIPR, a new regulator of death receptor-induced apoptosis. J Biol Chem 280 (2005) 14507-14513
21. Krueger A., Schmitz I., Baumann S., Krammer P.H., and Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276 (2001) 20633-20640
22. Micheau O., Thome M., Schneider P., Holler N., Tschopp J., Nicholson D.W., et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277 (2002) 45162-45171
23. Sharp D.A., Lawrence D.A., and Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280 (2005) 19401-19409
24. Varfolomeev E.E., Schuchmann M., Luria V., Chiannilkulchai N., Beckmann J.S., Mett I.L., et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 9 (1998) 267-276
25. Yeh W.C., Pompa J.L., McCurrach M.E., Shu H.B., Elia A.J., Shahinian A., et al. FADD: essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 279 (1998) 1954-1958
26. Dutton A., O'Neil J.D., Milner A.E., Reynolds G.M., Starczynski J., Crocker J., et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc Natl Acad Sci USA 101 (2004) 6611-6616
27. Galligan L., Longley D.B., McEwan M., Wilson T.R., McLaughlin K., and Johnston P.G. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther 4 (2005) 2026-2036
28. Rogers K.M., Thomas M., Galligan L., Wilson T.R., Allen W.L., Sakai H., et al. Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther 6 (2007) 1544-1551
29. Wilson T.R., McLaughlin K.M., McEwan M., Sakai H., Rogers K.M., Redmond K.M., et al. c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 67 (2007) 5754-5762
30. Day T.W., Najafi F., Wu C.H., and Safa A.R. Cellular FLICE-like inhibitory protein (c-FLIP): A novel target for Taxol-induced apoptosis. Biochem Pharmacol 71 (2006) 1551-1561 Epub 2006 Mar 31
31. Ganten T.M., Haas T.L., Sykora J., Stahl H., Sprick M.R., Fas S.C., et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11 (2004) S86-96
32. Naito M., Katayama R., Ishioka T., Suga A., Takubo K., Nanjo M., et al. Cellular FLIP inhibits beta-catenin ubiquitylation and enhances Wnt signaling. Mol Cell Biol 24 (2004) 8418-8427
33. Shimada K., Nakamura M., Matsuyoshi S., Ishida E., and Konishi N. Specific positive and negative effects of FLIP on cell survival in human prostate cancer. Carcinogenesis 27 (2006) 1349-1357
34. Golks A., Brenner D., Krammer P.H., and Lavrik I.N. The c-FLIP-NH2 terminus (p22-FLIP) induces NF-kappaB activation. J Exp Med 203 (2006) 1295-1305
35. Wang W., Wang S., Song X., Sima N., Xu X., Luo A., et al. The relationship between c-FLIP expression and human papillomavirus E2 gene disruption in cervical carcinogenesis. Gynecol Oncol 105 (2007) 571-577
36. Chen H.X., Liu Y.J., Zhou X.D., and Luo R.Y. Expression of cellular FLICE/caspase-8 inhibitory protein is associated with malignant potential in endometrial carcinoma. Int J Gynecol Cancer 15 (2005) 663-670
37. Zhou X.D., Yu J.P., Chen H.X., Yu H.G., and Luo H.S. Expression of cellular FLICE-inhibitory protein and its association with p53 mutation in colon cancer. World J Gastroenterol 11 (2005) 2482-2485
38. Rathore N., Matta H., and Chaudhary P.M. An evolutionary conserved pathway of nuclear factor-kappaB activation involving caspase-mediated cleavage and N-end rule pathway-mediated degradation of IkappaBalpha. J Biol Chem 279 (2004) 39358-39365
39. Sun S.Y., Liu X., Zou W., Yue P., Marcus A.I., and Khuri F.R. The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. J Biol Chem 282 (2007) 18800-18809
40. Willingham M.C. Cytochemical methods for the detection of apoptosis. J Histochem Cytochem 47 (1999) 1101-1110
41. Longley D.B., Wilson T.R., McEwan M., Allen W.L., McDermott U., Galligan L., et al. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25 (2006) 838-848
42. Jin T.G., Kurakin A., Benhaga N., Abe K., Mohseni M., Sandra F., et al. Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. J Biol Chem 279 (2004) 55594-55601
43. Xu G., and Shi Y. Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res 17 (2007) 759-771
44. Safa A.R., Day T.W., and Wu C.H. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets 8 (2008) 37-46
45. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., and Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12 (2000) 611-620
46. Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., and Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 26 (2006) 7046-7055
47. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., Deforge L., et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280 (2005) 2205-2212
48. Park S.J., Wu C.H., Choi M.R., Najafi F., Emami A., and Safa A.R. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem Pharmacol 72 (2006) 293-307
49. Wu C., Kao C., and Safa A.R. TRAIL recombinant adenovirus triggered robust apoptosis in multidrug resistant HL-60/Vinc cells preferentially through the death receptor DR5. Hum Gene Ther 13 (2008) 13
50. Yang J.K., Wang L., Zheng L., Wan F., Ahmed M., Lenardo M.J., et al. Crystal structure of MC159 reveals molecular mechanism of DISC assembly and FLIP inhibition. Mol Cell 20 (2005) 939-949
51. Engels I.H., Totzke G., Fischer U., Schulze-Osthoff K., and Janicke R.U. Caspase-10 sensitizes breast carcinoma cells to TRAIL-induced but not tumor necrosis factor-induced apoptosis in a caspase-3-dependent manner. Mol Cell Biol 25 (2005) 2808-2818
52. Chan F.K., Chun H.J., Zheng L., Siegel R.M., Bui K.L., and Lenardo M.J. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288 (2000) 2351-2354
53. Micheau O., Solary E., Hammann A., and Dimanche-Boitrel M.T. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 274 (1999) 7987-7992
54. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 320 (2004) 165-169
55. Martin S., Phillips D.C., Szekely-Szucs K., Elghazi L., Desmots F., and Houghton J.A. Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae. Cancer Res 65 (2005) 11447-11458
56. Delmas D., Rebe C., Micheau O., Athias A., Gambert P., Grazide S., et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 23 (2004) 8979-8986
57. Kataoka T., Budd R.C., Holler N., Thome M., Martinon F., Irmler M., et al. The caspase-8 inhibitor FLIP promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol 10 (2000) 640-648
58. Liu X., Yue P., Schonthal A.H., Khuri F.R., and Sun S.Y. Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res 66 (2006) 11115-11119
59. Zhang L., Zhang X., Barrisford G.W., and Olumi A.F. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 251 (2007) 146-157 Epub 2006 Dec 20
60. Kabore A.F., Sun J., Hu X., McCrea K., Johnston J.B., and Gibson S.B. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis 11 (2006) 1175-1193
61. Guo F., Sigua C., Tao J., Bali P., George P., Li Y., et al. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 64 (2004) 2580-2589